Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
http://investorshub.advfn.com/uimage/uploads/2023/11/25/tptneawinner.jpg">http://investorshub.advfn.com/uimage/uploads/2023/11/25/tptneawinner.jpg" />[/img]
The Company ESPR has a Miracle Drug. Amgen, MERK, PFIZER all interested in making Money.
The company may get bought out, but $.4.00 a share is about $100.00 per share too low.
Concerning Patents....
U.S. Patents filed after June 8, 1995 expire 20 years from the date of filing.
U.S. Patents filed prior to June 8, 1995 expire 17 years from the date of issue, or 20 years from the first non-provisional patent application in the family - whichever is later.
http://jolt.law.harvard.edu/articles/pdf/v26/26HarvJLTech403.pdf
a competitor may not even begin testing a potential competing product until after the patent expires. This is not problematic in most fields that are not subject to such heavy regulation because, in most circumstances,
competitors can rapidly enter the market soon after the patent
covering the relevant product expires. In the drug and medical device context, however, a competitor (such as a generic drug manufacturer) may not begin pursuing FDA approval or conducting U.S.-based clinical trials until the patent expires.93
A competitor’s product would therefore not reach the market until long after the patent had expired,
creating a de facto patent term extension for the patent holder.
94 1. § 156’s Patent Term Extension
The Hatch-Waxman Act added 35 U.S.C. § 156, which is meant
to remedy the de facto patent term reduction caused by FDA review
by granting an extension to the patent term.
95 In theory, the extension
provided by § 156 should exactly offset this lost time,96 which may otherwise unfairly disadvantage drug and device manufacturers as compared to patentees in other industries.
Facially, the Hatch-Waxman Act applies only to patents covering
drugs, but the Supreme Court has held that it applies equally to medical devices. 97 The extension is therefore available from the USPTO for medical device patents that claim a product or a method of using or manufacturing a product.98 Nonetheless, the statute provides an extension only for patents on products that are subject to a “regulatory review period.
PMCB like most companies with promising technology has nothing to worry about.
CIAB is Proprietary ( brand or item protected by intellectual property rights)
Yes, This looks like it has gotten a new floor at .151.. I had a feeling that the stock was gathering new followers and some of the larger houses have been taking notice. I can say that with all of Vonn Hoff's work and all the articles about CIAB.. Has not hurt in the least.
Remember that CIAB is a Process.. Once approved , can be used to treat many diseases.
The reduction of Chemo is a plus to those who have a hard time tolerating the side effects.
." This is targeted chemotherapy in every sense of the word with benefits not normally seen when a patient is undergoing chemotherapy.
Using Cell-in-Box allows PharmaCyte Biotech to use only one-third the normal dose of ifosfamide normally given to fight cancer. The proximity of the activation to the tumor site lessens the amount of ifosfamide required and, in turn, virtually eliminates the side effects usually seen with chemotherapy. "
From today's news release
Luco... Bet they have no system like CIAB... That they can license for each medication used, and for each type of disease...
That is what makes PMCB such a great company... They own the world wide rights and can license to the highest bidder....
I believe the money is in the licensing of the use...
let's see... Squeeze out the week hands... From what i am seeing, there are not a lot of weak hands.
The product works.. Is saleable.. And the science is good.. $3-$5 is my best Guess.
HEB Undervalued.... The aleferon and Ampligen are good science. This is a buy,
I agree... When they give the permission to study... It could be very exciting.. We all know that it was wrong of NIXON to put MJ on the list.
The herb was studied by the Israeli's back in the 80's and 90's.. And approved for use in their country. This war on drugs has cost countless dollars and lives ruined.
When our daughter passed from Leukemia, they gave us a case (24) vials of morphine for the pain.. It had little to no effect.
I would have been happy to have something for her that was natural and could have really taken the edge off her pain.
I Agree...
Remember DISEASE is two words... DIS EASE.. Anything that can take away or "ease" the process of re leaving pain.. Such as CIAB.. has demonstrated so far.... or Repair... As CIAB can be used for Diabetes, to lessen the Insulin INJECTIONS and possibly correct the DIS-EASE... needs to come to Market as FAST as possible.
Regardless of who owned what.. Science has changed.. Maybe it would pay Big Pharma to retry some of there failed attempts from the past..
Remember VIAGRA was first available for HYPERTENSION....DUH.....
And as the History goes, No one was interested in the tech.... So Austranova went B.K and NVLX... seeing an opportunity, bought the tech rights... The Company paid 2 Million for CIAB technology... Partnering with Austranova and doing the research to make CIAB VIABLE.
Now the Science is being proven. Through new discoveries,using "LESS CHEMO," THE SCIENCE WORKS.
The BIG PHARMA.. Greed driven is scratching there heads in wonder. How could they let this get this far... And they are doing what they can to slow the process, while PMCB continues to follow the process forward and report in Journals world wide....THAT THE SCIENCE WORKS and will revolutionize the way MEDICINE is used to CURE Dis Ease....
HEB.. Ampligen works.. And the company has the production capability. I would say that the nay Sayers are going to be wondering what happened and why. I also would say big Pharma was behind a lot of the bad mouthing...
The Science is Good.. HEB is now combating the Nay Sayers head on.. I am LONG.
Reviews
Vaccine adjuvant uses of poly-IC and derivatives
March 2015, Vol. 14, No. 3 , Pages 447-459 (doi:10.1586/14760584.2015.966085)
HTML
PDF (489 KB)
PDF Plus (497 KB)
Reprints
Permissions
Karen AO Martins, Sina Bavari, and Andres M Salazar
1USAMRIID,
1425 Porter Street, Fort Detrick, MD 21702,
USA
2Oncovir,
3203 Cleveland Ave, NW, Washington, DC, 20008,
USA
*Author for correspondence+1 202 321 6345 +1 202 248 2324 asalazar@oncovir.com
Pathogen-associated molecular patterns (PAMPs) are stand-alone immunomodulators or ‘danger signals,’ that are increasingly recognized as critical components of many modern vaccines. Polyinosinic-polycytidylic acid (poly-IC) is a synthetic dsRNA that can activate multiple elements of the host defense in a pattern that parallels that of a viral infection. When properly combined with an antigen, it can be utilized as a PAMP-adjuvant, resulting in modulation and optimization of the antigen-specific immune response. We briefly review the preclinical and clinical uses of poly-IC and two poly-IC derivatives, poly-IC12U (Ampligen) and poly-ICLC (Hiltonol), as vaccine adjuvants.
Keywords
Adaptive immunity, adjuvant, ampligen, hiltonol, innate immunity, interferons, PAMP, poly-IC, poly-ICLC, TLR3, vaccine
Read More: http://informahealthcare.com/doi/abs/10.1586/14760584.2015.966085
Austrianova’s Cell-in-a-Box® technology was recently featured in the December issue of the Journal of the National Cancer Institute in an article entitled "New Approaches Tackle Rising Pancreatic Cancer Rates” by scientific journalist Vicki Brower. The article summarizes promising treatments currently in development for pancreatic cancer and includes our Cell-in-a-Box® approach and the clinical trial data obtained to date. This application of our Cell-in-a-Box® technology is being developed with PharmaCyte Biotech
http://jnci.oxfordjournals.org/content/106/12/dju417.full
'Another approach aims to make pancreatic cancer an operable disease. Using “Cell in a Box” technology developed by Austrianova, in Singapore, this cell therapy delivers ifosfamide locally to the cancer. Ifosfamide has previously shown promise as a chemotherapy against pancreatic cancer, but its effective dose was too toxic to give patients systemically. Instead, in the “Cell in the Box” approach, patients receive one-third of the usual dose of ifosfamide. “Cell in a Box” contains genetically modified cells that express the drug-metabolizing cytochrome P450 and converts the ifosfamide to its active form at the site of the tumor, according to CEO Brian Salmons, Ph.D. A catheter delivers the “Cell in a Box” capsule containing these cells to capillaries feeding the pancreas. This system of local delivery and activation greatly reduces side effects.
The European Medicines Agency fast-tracked this treatment, which is licensed to Nuvilex (Silver Spring, Md.). "
"
Me Too Pete.. This a no Brainer at these prices..
Look, True Longs know what it takes to get a medical device, or new drug to market.
The opportunities here are tremendous.
With Cell in a box, this company has a powerful opportunity to change the way Chemo and Diabetes is managed and possibly cured.
The company has the international license and will make millions if not billions in licensing fee's for CIAB
The Doctors they have in place are the best in the field. Von Hoff has seen and brought cancer drugs through the system.
THE SCIENCE WORKS.
Long and Strong, and recommend any with questions to do your own Due Diligence. Check out the company web site...look up the information on the DOCTORS involved and ask yourself.... If I were a Doctor with a stellar reputation, would I go to work for a company if the SCIENCE did not work?
It's good Science.. CIAB will revolutionize the way DISEASE is treated.
This is amazing science. If CIAB has less complications and creates a better way to deliver relief from these diseases, it will revolutionize the way Diabetes and Cancer is treated. Less Chemo used, and a better treatment through less damage to the body.